ClinicalTrials.gg
CompletedNCT06713447Updated Sep 9, 2026

NTI164 Human PK Study

A Phase 1 interventional study of NTI164 in Healthy and Healthy Volunteer, sponsored by Fenix Innovation Group. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Fenix Innovation Group · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2024, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is looking at how a new cannabis compound with extremely low THC (0.08%), NTI164, is metabolised in the body and how it is excreted in urine over time (up to 28 days) in healthy adult volunteers. NTI164 will be delivered twice daily, at a concentration of 20mg/kg/day. There will be 2 parts to this study, Part A and Part B. Part A involves only one day of taking NTI164, whereas Part B involves taking NTI164 for 7 consecutive days. Urine samples and blood samples will be collected at certain time points after NTI164 dosing to help characterise how the drug is being broken down in the body and over what time frame.

Read the detailed description

This open-label study aims to assess the efficacy of Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC (NTI164) in healthy adult volunteers. The main objective is to characterise the pharmacokinetic (PK) profile of NTI164 in the body. This study is split into 2 Parts, with NTI164 delivered orally twice daily at a dose of 20mg/kg/day (i.e. 2 x 10mg/kg doses), and blood and urine samples collected in both parts.

Part A involves only one day of NTI164 administration. In Part A, an oral dose of NTI164 will be administered to participants in a fasted state in the morning (AM). Blood samples will be collected at pre-dose and then 0.5, 2, 4, 6, and 8 hours following the AM dose. In the evening (PM), participants will receive another dose of NTI164 and bloods will be collected pre-PM dose, and 0.5, 2, 4, 6, 8, 12, and 24 hours following the PM dose.

On Day 3 and 4, only one blood sample will be collected in the morning. Urine samples will be collected pre-AM dose, as well as 4, 8, 12, and 24 hours following, and 4, 8, 16, and 24 hours following the PM dose. Following the 24-hour post-PM dose urine sample, urine samples will be collected every 6 hours until 72 hours after the initial AM dose on Day 1 (i.e. AM on Day 4).

Following blood and urine sample collection on Day 4, participants may be discharged from the clinical facility and will return on Day 7 to provide a final blood and urine sample. A follow-up phone call will be made to participants on Day 14 to ensure no adverse events have occurred and there are no concerns.

In Part B, NTI164 will be administered for 7 consecutive days. Participants will not need to be fasted for Part B. On Day 1 (day of first dose), blood samples will be collected at pre-dose and then 0.5, 2, 4, 6, and 8 hours following the AM dose. In the evening (PM), participants will receive another dose of NTI164, and bloods will be collected 0.5, 2, 4, 6, 8, 12, and 24 hours following the PM dose.

Urine samples will be collected pre-AM dose, as well as 4, 8, 12, and 24 hours following, and 4, 8, 16, and 24 hours following the PM dose. On Day 3, blood and urine samples will be collected pre-AM dose, and participants will be discharged and will continue at-home administration of NTI164.

Participants will return on Day 6 as intensive blood and urine sampling will occur once again on Day 7. On Day 7, blood samples will be collected at pre-dose and then 0.5, 2, 4, 6, 8, and 12 hours following the AM dose. In the evening (PM), participants will receive another dose of NTI164 (FINAL dose of the study), and bloods will be collected 0.5, 2, 4, and 24 hours (Day 8) following the PM dose. Urine samples will be collected pre-AM dose, as well as 4, 8, 12, and 24 hours following, and 4, 8, 16, and 24 hours following the PM dose.

The PM dose on Day 7 will be the final dose of NTI164 administered, however, participants will need to remain in the clinical facility on Day 8 for sample collection. A final blood and urine sample will be collected Day 9 AM, and then participants will be discharged from the clinical facility. Participants will return to the clinical facility for a blood and urine sample in the morning on Day 14, and also on Day 21 for a follow-up visit and final blood sample (no urine to be collected at this visit). This will mark the end of the study.

02

Conditions studied

  • Healthy
  • Healthy Volunteer

Keywords

  • Pharmacokinetic
  • Healthy
  • Cannabis
03

In context

Lead sponsor

Fenix Innovation Group is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written before any study-related activities are performed and must be able to understand the full nature and purpose of the study, including possible risks and AEs.
  2. Adult males and females, 18 to 65 years of age (inclusive) at screening.
  3. ≥ 18.0 and ≤ 32.0 kg/m2, with a body weight of at least 50 kg.
  4. Medically healthy (in the opinion of the Investigator), as determined by pre-study medical history and without abnormalities. Must have:

    1. Physical examination without any clinically relevant findings;
    2. Systolic blood pressure (BP) in the range of 90 to 145 mmHg and diastolic BP in the range of 50 to 95 mmHg after resting for 5 minutes in a supine position.
    3. Pulse rate in the range of 45 to 100 bpm after 5 minutes resting in a supine position.
    4. Body temperature (tympanic), between 35.5°C and 37.7°C.
    5. (ECG) without clinically significant abnormalities including corrected for Fredericia (QTcF) \<450 msec, QRS interval \< 120 msec and PR interval \< 220 msec, based on the average of triplicate measurements.
    6. No clinically significant findings in serum chemistry, haematology, coagulation, and urinalysis tests.
  5. Female participants:

    1. Must be of non-, i.e., surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy) at least 6 weeks before the screening visit or (with postmenopausal defined as no menses for 12 months without an alternative medical cause and a follicle-stimulating hormone (FSH) level consistent with postmenopausal status, per local laboratory guidelines), or
    2. If of child-bearing potential, must:

    i. Have a negative pregnancy test at the screening visit and on admission to the study site on Day-1. ii. Agree not to attempt to become pregnant or donate ova from signing the consent form until at least 30 days after the last dose of study drug. iii. Agree to use adequate (defined as use of a condom by the male partner combined with use of a highly effective method of contraception (e.g. hormonal contraception, intrauterine device, bilateral tube occlusion, etc.) from one month prior to screening until at least 30 days after the last dose of study drug, if not exclusively in a same-sex relationship or abstinent as a committed lifestyle.

  6. Male participants:

    1. Must agree not to donate sperm from signing the consent form until at least 90 days after the last dose of study drug.
    2. If engaging in sexual intercourse with a female partner who could become pregnant, agree to use adequate contraception (defined as use of a condom combined with use of a highly effective female method of contraception (as above)) from signing the consent form until at least 90 days after the last dose of study drug.
    3. If engaging in sexual intercourse with a female partner who is not of childbearing potential or a same-sex partner, agree to use a condom from signing the consent form until at least 90 days after the last dose of study drug.
    4. Practise true abstinence: when this is in line with their preferred and usual lifestyle.
  7. Have suitable venous access for blood sampling.
  8. Abstain from alcohol for the duration of the study period.
  9. Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Known to any of the study drug ingredients.
  2. History of anaphylaxis or other significant allergy (including system sensitivity to any aerosol) which, in the opinion of the Investigator, would interfere with the participant's ability to participate in the study.
  3. History or presence of cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric, or neurological disease/disorder, including any acute illness, determined by the Investigator to be clinically relevant.
  4. Current diagnosis of bipolar disorder, major depressive disorder, psychosis, schizophrenia, or schizoaffective disorder.
  5. History of major surgery or hospitalisation within 12 weeks prior to screening, or surgery planned during the study.
  6. History of malignant disease in the last 10 years (excludes surgically resected skin squamous cell or basal cell carcinoma).
  7. Clinically relevant history or presence of rhythm disorders (e.g. sinoatrial heart block, second- or third-degree atrioventricular block, long syndrome, symptomatic bradycardia, atrial flutter, or atrial fibrillation), clinically-relevant history of hypokalaemia, congestive heart failure, or structural heart disease.
  8. Presence or having sequelae of gastrointestinal, liver (with the exception of Gilbert's syndrome), kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  9. Serum or plasma potassium \<3.5 or >5.2 mmol/L, (ALT) or aspartate aminotransferase (AST) > 1.5 x (ULN), or total >2 x ULN at screening or Day -1 (except for Gilbert's syndrome).
  10. History of or positive test results for , , or antibodies at screening.
  11. Positive drugs of abuse test, urine cotinine test, and/or urine alcohol test results at screening and/or on admission to the clinical facility on Day -1.
  12. History or clinical evidence of alcoholism or drug abuse (in the opinion of the Investigator) within the 3-year period prior to screening.
  13. Regular consumption of >10 standard alcoholic beverages/week, where 1 standard drink is 10g of pure alcohol and is equivalent to 285 mL beer (4.9% Alc/Vol), 100 mL wine (12% Alc/Vol), or 30mL spirit (40% Alc/Vol).
  14. Excessive caffeine consumption, defined as ≥ 800 mg per day at screening (1 cup of coffee contains \~100 mg caffeine, 1 cup of tea or one glass of cola contains \~40 mg caffeine, 1 can of Red Bull contains \~80 mg caffeine).
  15. Females who are pregnant, breastfeeding, or planning to breastfeed.
  16. Use of any prescribed medications (including vaccines) or over-the-counter medications (including herbal medicines, such as St John's Wort, homeopathic preparations, dietary supplements, vitamins, and minerals) within 2 weeks (or 5 half-lives, whichever is longer) prior to (first) study treatment administration, except the use of , and occasional use of paracetamol and/or ibuprofen (at the discretion of the Investigator).
  17. Received any vaccinations within 14 days prior to screening.
  18. Donation of blood or plasma within 12 weeks prior to screening, loss of whole blood of >500mL within 12 weeks prior to first dose of study drug, or receipt of a blood transfusion within 1 year of first dose of study drug.
  19. Participation in another clinical study of an drug or device within 12 weeks prior to screening.
  20. Any other condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.
  21. Currently using or has used recreational or medicinal cannabis or cannabinoid-based medications within the 12 weeks prior to screening and is unwilling to abstain for the duration of the study.
  22. Had brain surgery or a traumatic brain injury within 1 year of screening.
  23. History of suicidal behaviour or suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the 12 weeks prior to screening and in ongoing assessment throughout the study.
  24. Has previously been enrolled in this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    NTI164 active

    All participants will be in this arm (single intervention) and will receive NTI164.

    Drug: NTI164

Interventions

  • DrugNTI164

    This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164) specifically formulated to target inflammation in various neurological conditions. The dose of 20mg/kg has been selected based off existing clinical trial evidence for NTI164, and is similar to the dose of other cannabis-based drugs used in neurology. The safety of NTI164 has been rigorously tested in several ongoing paediatric clinical trials through blood tests and clinician-rated surveys.

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration (Cmax)

    Maximum concentration of the drug at timepoints: baseline (pre-dose), 1, 2, 3, 4, 5, 12, 24 hrs post commencement of treatment, and daily up to 7 days post-dose for Part A and 21 days for Part B.

    Time frame: Up to 21 days

Secondary outcomes

  1. Ae t1-t2 - urine

    Amount of drug excreted in urine at timepoints: baseline (pre-dose), 1, 2, 3, 4, 5, 12, 24 hrs post commencement of treatment, and daily up to 7 days post-dose for Part A and 21 days for Part B.

    Time frame: Up to 21 days

07

Study locations

1 site
  • CMAX Clinical Research Pty Ltd
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared as per commercial in confidence restrictions.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jun 2025, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Dec 3, 2024
StartActual
Feb 1, 2024
Primary completionActual
Jun 1, 2025
CompletionActual
Jun 1, 2025
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06713447
Lead sponsor
Fenix Innovation Group
Collaborators
CMAX Clinical Research Pty Ltd, Neurotech International Limited
Responsible party
Sponsor
First posted
Dec 3, 2024
Start date
Feb 1, 2024
Primary completion
Jun 1, 2025
Completion
Jun 1, 2025
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NTI164

Start the discussion